The Future of
We are a biotech startup focusing on the discovery and development of next generation antibody-based therapeutics.
Founded in April 2018, our senior management team has a wealth of experience in the US, UK and China, in the development of antibody therapeutics that have reached commercialization. These include Yervoy, Nulojix, Orencia, Humira, Tyvyt, and Trobalt. By March 2019, a total of $35 million was raised to fund our expanding therapeutics pipeline and bring products closer to the clinic.
Our HQ is located in Zhuhai, China, with R&D capabilities including antibody discovery, process development and analytical assessment platforms, including a pilot plant that would facilitate IND-enabling activities.
We also have R&D labs at Suzhou and Hong Kong Science & Technology Park (HKSTP) to study the mechanisms of Treg cells and innate immunity in cancer.
Zhuhai HQ10B, Building 4, No 1 Keji 7th Road
Xiang Zhou District
ChinaTel: +86 756 6998555
Fax: +86 756 6998701Email: firstname.lastname@example.org
Suzhou3/F Room 309, Block D
398 Ruoshui Road
Hong KongUnit 611 Biotech Centre 2
Hong Kong Science and Technology Park
11 Science Park West Ave